|
|
Outside of clinical trial, in what settings would you use these novel agents for WM?Outside of clinical trial, in what settings would you use these novel agents for WM?In what situations, if any, would you attempt to use ibrutinib for WM outside a clinical trial setting? In what situations, if any, would you attempt to use carfilzomib for WM outside a clinical trial setting?
Chakraborty R et al. Ibrutinib for the treatment of Waldenström macroglobulinemia. Expert Rev Hematol 2015;[Epub ahead of print]. Abstract Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: Prognosis and management. Blood Cancer J 2015;5:e296. Abstract Treon SP et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372(15):1430-40. Abstract Treon SP et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood 2014;124(4):503-10. Abstract |